Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas. (Q45988106)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23143694%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

title

Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23143694%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23143694%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Muhammad Baghdadi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23143694%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Hironori Yoshiyama

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23143694%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

author name string

Hiroko Nagao

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23143694%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Hisaya Akiba

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23143694%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Hideo Yagita

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23143694%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Hirotoshi Dosaka-Akita

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23143694%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Masahisa Jinushi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23143694%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

publication date

10 November 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23143694%20AND%20SRC:MED&resulttype=core&format=json

Cancer Immunology, Immunotherapy

17 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23143694%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

volume

62

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23143694%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23143694%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

page(s)

629-637

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23143694%20AND%20SRC:MED&resulttype=core&format=json

Immune therapy for cancer

17 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

Cancer vaccines for established cancer: how to make them better?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

Immunosuppressive strategies that are mediated by tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

Mechanisms of immune evasion by tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

Targeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

Prospects for TIM3-Targeted Antitumor Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

Tim-3, a negative regulator of anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

Identification of Tim4 as a phosphatidylserine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

T and B cell hyperactivity and autoimmunity associated with niche-specific defects in apoptotic body clearance in TIM-4-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

Milk fat globule epidermal growth factor-8 blockade triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

New aspects of natural-killer-cell surveillance and therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

Macrophage diversity enhances tumor progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

Immune microenvironments in solid tumors: new targets for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

Regulation of adaptive immunity by the innate immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

The role of innate immune signals in antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

Immunogenic and tolerogenic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1371-9

10.1007/S00262-012-1371-9

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23143694%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

17 February 2020

1001133461

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23143694%20AND%20SRC:MED&resulttype=core&format=json